Sayana® Press Extension Study

PHASE3CompletedINTERVENTIONAL
Enrollment

750

Participants

Timeline

Start Date

September 22, 2017

Primary Completion Date

May 30, 2020

Study Completion Date

November 18, 2020

Conditions
Contraception
Interventions
DRUG

Sayana® Press

The active ingredient in Sayana® Press is Medroxyprogesterone acetate (MPA). Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) for subcutaneous injection.

Trial Locations (3)

13084-971

Universidade Estadual de Campinas (UNICAMP), Campinas

Unknown

Instituto Chileno De Medicina Reproductiva (ICMER), Santiago

Asociación Dominicana Pro Bienestar de la Familia, Inc. (PROFAMILIA), Santo Domingo

All Listed Sponsors
lead

FHI 360

OTHER

NCT03154125 - Sayana® Press Extension Study | Biotech Hunter | Biotech Hunter